Johnson & Johnson unit ordered to pay $1.64 billion in HIV drug marketing case
A federal judge ordered a Johnson & Johnson unit on Friday to pay the U.S. government $1.64 billion after a jury found it ...
STAT15h
Pharmalittle: We’re reading about a pharma tariff exception, FDA inspection cutbacks, and more
The Trump administration carved out an exception for pharmaceuticals from the president's new tariff regime, at least for now ...
Fierce Pharma3d
Judge levies $1.64B penalty on Johnson & Johnson in HIV drug marketing case
Nearly a year after a jury decided that Johnson & Johnson should be fined just over $150 million in a lawsuit alleging that ...
Hosted on MSN13d
FDA approves Johnson & Johnson’s Tremfya to treat Crohn’s disease
Johnson & Johnson (J&J) has received US Food and Drug Administration (FDA) approval for its interleukin 23 inhibitor, Tremfya ...
Becker's Hospital Review2d
J&J hit with $1.64B penalty for illegal drug marketing practices
A federal judge has ordered Johnson & Johnson’s Janssen unit to pay $1.64 billion for illegally promoting HIV drugs Prezista ...
Johnson & Johnson Closes Landmark Intra-Cellular Therapies, Inc. Acquisition to Solidify Neuroscience Leadership
Johnson & Johnson (NYSE: JNJ) today announced it has completed its acquisition of Intra-Cellular Therapies, Inc. Intra-Cellular Therapies is now part of Johnson & Johnson and will operate as a ...
Janssen Liability Increased to $1.6 Billion in Drug Fraud Suit
Janssen Products LP must pay over $1.6 billion in a False Claims Act suit for improperly billing the US government for HIV ...
The American Journal of Managed Care13d
FDA Approves Guselkumab for Adult Patients With Crohn Disease
The FDA has approved guselkumab (Tremfya) as the first IL-23 inhibitor offering both subcutaneous and intravenous induction ...
Healio13d
Tremfya’s FDA win as fully subcutaneous option for Crohn’s may pave way to eclipse Stelara
The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...
FDA Approves Johnson & Johnson's Tremfya For Crohn's Disease
Johnson & Johnson's Tremfya gains FDA approval for Crohn's disease, backed by Phase 3 trial data and demonstrating ...
Yahoo Finance13d
FDA approves Johnson & Johnson’s Tremfya to treat Crohn’s disease
Johnson & Johnson (J&J) has received US Food and Drug Administration (FDA) approval for its interleukin 23 inhibitor, Tremfya (guselkumab), to treat moderately to severely active Crohn's disease ...